Tudor Investment Corp ET AL Acquires New Position in Jounce Therapeutics, Inc. (JNCE)

Tudor Investment Corp ET AL acquired a new stake in Jounce Therapeutics, Inc. (NASDAQ:JNCE) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $2,199,000. Tudor Investment Corp ET AL owned approximately 4.13% of Jounce Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the company. Laurion Capital Management LP acquired a new stake in shares of Jounce Therapeutics during the first quarter valued at approximately $880,000. Omega Fund Management LLC purchased a new position in shares of Jounce Therapeutics during the first quarter valued at about $12,747,000. Wellington Management Group LLP purchased a new position in shares of Jounce Therapeutics during the first quarter valued at about $34,814,000. EcoR1 Capital LLC bought a new position in Jounce Therapeutics during the first quarter worth $5,683,000. Finally, Spark Investment Management LLC bought a new position in Jounce Therapeutics during the first quarter worth $1,345,000. 39.35% of the stock is owned by institutional investors and hedge funds.

Shares of Jounce Therapeutics, Inc. (JNCE) traded up 0.72% during midday trading on Wednesday, reaching $13.92. The company’s stock had a trading volume of 51,947 shares. Jounce Therapeutics, Inc. has a 12 month low of $13.68 and a 12 month high of $29.29. The company’s 50-day moving average price is $19.35 and its 200-day moving average price is $21.38. The company’s market cap is $447.82 million.

Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Tuesday, May 9th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.07. The company had revenue of $20.30 million during the quarter, compared to analyst estimates of $19.71 million. The business’s quarterly revenue was up 202900.0% on a year-over-year basis. On average, equities analysts anticipate that Jounce Therapeutics, Inc. will post ($0.65) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Tudor Investment Corp ET AL Acquires New Position in Jounce Therapeutics, Inc. (JNCE)” was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/07/12/100000-shares-in-jounce-therapeutics-inc-jnce-acquired-by-tudor-investment-corp-et-al-updated-updated.html.

A number of analysts recently commented on JNCE shares. Zacks Investment Research downgraded Jounce Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 12th. Cowen and Company reissued a “buy” rating on shares of Jounce Therapeutics in a research report on Thursday, April 20th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Jounce Therapeutics has a consensus rating of “Buy” and a consensus price target of $28.67.

About Jounce Therapeutics

Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.

Institutional Ownership by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply